● Past and current treatment regimens and responses, including adverse effects or reactions. ● How pain impacts physical and psychological function. ● How pain influences sleep, mood, work, relationships, leisure, and substance use. ● Identification of concurrent conditions that may increase the risk for adverse events (e.g., obesity, renal disease, sleep apnea, COPD). ● Review of current medications; identify interacting drugs and other central nervous systems (CNS) depressants. ● Social support, housing, employment, or recent military deployment. ● Patient and family history of mental health disorders (e.g., bipolar, attention deficit disorder program, physical medicine, psychological and behavioral strategies, or medications (nonopioids and opioids), depending upon the physical and psychosocial issues related to the pain. Opioid therapy is not the appropriate first-line treatment for most patients with chronic pain. It should be reserved for intractable chronic pain that is not adequately managed with more conservative or interventional methods. Other nonopioid medications, treatment modalities, and nonpharmacological therapy should be tried first. Practitioners should document the effectiveness or failure of these medications before initiating opioid therapy. 100 Suppose the prescriber determines that an opioid trial is an appropriate treatment option. In that case, the patient, caregiver(s), and family member(s) are informed of the risks and benefits of opioid analgesic therapy and the conditions under which the opioids are being prescribed. A trial implies that opioids are used for a short period (i.e., weeks or a couple of months), and continued use will be contingent upon demonstrated improvement in pain, physical function, and quality of life with no significant adverse reactions or aberrant behaviors. 101 If the prescriber institutes long-term opioid therapy, a written informed consent and treatment agreement are recommended. The informed consent may address several issues, such as the following: ● Limited evidence of the benefit of opioids or other medications in managing chronic pain (except for cancer). ● Potential risks and benefits of opioid therapy. ● Potential short- and long-term side effects of opioid therapy. ● The likelihood that tolerance to and physical dependence on the medication will develop. ● Risk of drug interactions and oversedation. ● Risk of impaired motor skills.
(ADD) / attention deficit hyperactivity disorder (ADHD), depression, posttraumatic stress disorder). ● Patient and family history of substance use, addiction, or dependence. ● Determination of any history of physical, emotional, or sexual abuse and risk factors for substance abuse disorder; validated screening tools for substance abuse disorder help determine a patient’s risk level. ● Review of PDMP results. ● Monitoring of PDMP regularly throughout chronic pain management follow-up to determine if the patient obtains other controlled substance prescriptions from other providers. ● Risk of substance abuse disorder, overdose, and death. ● The clinician’s prescribing policies (e.g., number and frequency of refills, early refills, exceptions). ● Reasons a drug may be changed or discontinued; treatment may be discontinued without agreement from the patient, such as violations of the treatment agreement. ● Education for patients stating that complete elimination of pain should not be expected. Chronic pain treatment agreements that outline the responsibilities of the patient and the provider are indicated for long-term treatment with opioids or other medications with the potential for substance abuse disorder. The U.S. Department of Health and Human Services, Division of Indian Health Services, recommends that treatment agreements include the following tenets. 102 ● Treatment goals are defined in terms of pain management, restoration of function, and safety. ● The patient is responsible for safe medication use (i.e., not taking more than prescribed; understanding the dangers of using in combination with alcohol, cannabis, benzodiazepines, or other CNS depressants unless closely monitored by the prescriber). ● The patient will ensure secure storage and safe disposal. ● The patient will obtain opioids from only one clinician or practice. ● The patient will fill the opioids at only one pharmacy. ● The patient will agree to periodic drug testing (i.e., urine drug screening). ● The clinician is responsible for making themselves available or having a covering clinician available to care for unforeseen problems and to prescribe scheduled refills. Complete pain relief is often not achieved; a 30% reduction in pain is considered a good clinical response and a reasonable goal when managing patient expectations. 103 In a function-based treatment strategy for chronic pain, treatment efficacy is measured by the patient’s ability to achieve improved
Informed consent and treatment plans for chronic opioid treatment The patient-specific treatment plan should be developed and reviewed regularly to ensure that both the clinician and patient agree on the goals of the therapy, treatment regimen, and options. Consider different treatment modalities, such as an interventional approach, a formal pain rehabilitation
Book Code: MDCO1025
Page 69
Powered by FlippingBook